var data={"title":"Sulfadiazine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sulfadiazine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6997?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=sulfadiazine-drug-information\" class=\"drug drug_general\">see &quot;Sulfadiazine: Drug information&quot;</a> and <a href=\"topic.htm?path=sulfadiazine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Sulfadiazine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050008\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Sulfonamide Derivative</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11445119\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Congenital toxoplasmosis:</b> Oral: 100 mg/kg/day divided every 12 hours for 12 months in conjunction with pyrimethamine and supplemental leucovorin (CDC, 2009)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050001\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=sulfadiazine-drug-information\" class=\"drug drug_general\">see &quot;Sulfadiazine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants &lt;2 months: <b>Congenital toxoplasmosis:</b> Oral:  100 mg/kg/day divided every 12 hours for 12 months in conjunction with pyrimethamine and supplemental leucovorin (CDC, 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants &ge;2 months, Children, and Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: Initial: 75 mg/kg/dose or 2000 mg/m<sup>2</sup>/dose once followed by maintenance: 150 mg/kg/day or 4000 mg/m<sup>2</sup>/day divided every 4-6 hours; maximum daily dose: 6 <b>g/day </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: 120-150 mg/kg/day in divided doses 4-6 times daily; maximum daily dose: 6 g/<b>day</b> (<i>Red Book</i>, 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Toxoplasmosis</b> (CDC, 2009; <i>Red Book</i>, 2012): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Congenital:</i> Infants: 100 mg/kg/day divided every 12 hours for 12 months in conjunction with pyrimethamine </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Acquired:</i> Acute induction therapy:  Infants &ge;2 months, Children, and Adolescents: 100-200 mg/kg/day divided every 4-6 hours in conjunction with pyrimethamine and supplemental leucovorin; maximum daily dose: 6 g/<b>day</b>. Continue acute induction therapy for at least 6 weeks, then follow with chronic suppressive therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Secondary prophylaxis (HIV-exposed/-positive):</i> Infants &ge;2 months and Children: 85-120 mg/kg/day divided every 6-12 hours; in combination with pyrimethamine and leucovorin; maximum daily dose: 4000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Encephaltitis; Toxoplasma gondii; treatment (HIV-exposed/-positive)</i> (CDC, 2013): Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Acute therapy: At least 6 weeks of therapy recommended; use in conjunction with pyrimethamine and supplemental leucovorin combination therapy or with atovaquone </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Patient weight &lt;60 kg: 1000 mg every 6 hours </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Patient weight &ge;60 kg: 1500 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Chronic maintenance therapy: 2000-4000 mg/day in divided doses 2-4 times daily in conjunction with pyrimethamine and leucovorin or with atovaquone; begin after completion of acute therapy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rheumatic fever; secondary prophylaxis:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&le;30 kg: 500 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;30 kg: 1000 mg/day  </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing (Gerber, 2009; <i>Red Book</i>, 2012):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patient weight &le;27 kg: 500 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patient weight &gt;27 kg: 1000 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing:</b> Oral: Initial 2000-4000 mg once, followed by  2000-4000 mg/day in divided doses 3-6 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Toxoplasma gondii</i> encephalitis (HIV-exposed/-positive patients)</b> (CDC, 2013a): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Acute therapy: At least 6 weeks of therapy necessary; use in conjunction with pyrimethamine and leucovorin combination therapy or with atovaquone </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patient weight &lt;60 kg: 1000 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patient weight &ge;60 kg: 1500 mg every 6 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Chronic maintenance therapy: 2000-4000 mg/day in divided doses 2-4 times daily in conjunction with pyrimethamine and leucovorin or with atovaquone; begin after completion of acute therapy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rheumatic fever prophylaxis:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;30 kg: 500 mg/day </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;30 kg: 1000 mg/day </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223759\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223745\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050011\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer with at least 8 ounces of water and around-the-clock to promote less variation in peak and trough serum levels. In adults, oral sodium bicarbonate may be used to alkalinize the urine of patients unable to maintain adequate fluid intake (in order to prevent crystalluria, azotemia, oliguria) (Lerner, 1996)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3149216\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at controlled room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050010\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Adjunctive treatment in toxoplasmosis with pyrimethamine [FDA approved in ages &ge;2 months and adults (may be used in ages &lt;2 months for treatment of congenital toxoplasmosis)]</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Treatment of chancroid, trachoma, inclusion conjunctivitis,  urinary tract infections, and nocardiosis (not first line), treatment and prophylaxis of meningococcal meningitis, treatment of <i>H. influenza</i> meningitis, prophylaxis of rheumatic fever prophylaxis in penicillin-allergic patient, treatment of uncomplicated attack of malaria due to chloroquine-resistant <i>Plasmodium falciparum</i> (FDA approved in ages &ge;2 months and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223809\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">SulfADIAZINE may be confused with sulfaSALAzine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223807\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Allergic myocarditis, periarteritis nodosa</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Ataxia, chills, depression, hallucination, headache, insomnia, peripheral neuritis, seizure, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Erythema multiforme, exfoliative dermatitis, pruritus, skin photosensitivity, skin rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypoglycemia, thyroid dysfunction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, diarrhea, nausea, pancreatitis, stomatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Crystalluria, diuresis, toxic nephrosis (with anuria and oliguria)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Agranulocytosis, aplastic anemia, hemolytic anemia, hypoprothrombinemia, leukopenia, methemoglobinemia, purpura, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylactoid reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Serum sickness-like reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, lupus erythematosus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Conjunctival injection, injected sclera, periorbital edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Nephrolithiasis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223764\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to any sulfa drug or any component of the formulation; infants &lt;2 months of age unless indicated for the treatment of congenital toxoplasmosis; pregnancy (at term); breast-feeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223749\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Blood dyscrasias: Fatalities associated with severe reactions including agranulocytosis, aplastic anemia and other blood dyscrasias have occurred; discontinue use at first sign of rash or signs of serious adverse reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Dermatologic reactions: Fatalities associated with severe reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have occurred; discontinue use at first sign of rash.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic necrosis: Fatalities associated with hepatic necrosis have occurred; discontinue use at first sign of rash.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sulfonamide (&ldquo;sulfa&rdquo;) allergy: Traditionally, concerns for cross-reactivity have extended to all compounds containing the sulfonamide structure (SO<sub>2</sub>NH<sub>2</sub>). An expanded understanding of allergic mechanisms indicates cross-reactivity between antibiotic sulfonamides and nonantibiotic sulfonamides may not occur, or at the very least this potential is extremely low (Brackett 2004; Johnson 2005; Slatore 2004; Tornero 2004). In particular, mechanisms of cross-reaction due to antibody production (anaphylaxis) are unlikely to occur with nonantibiotic sulfonamides and antibiotic sulfonamides. A nonantibiotic sulfonamide compound which contains the arylamine structure and therefore may cross-react with antibiotic sulfonamides is sulfasalazine (Zawodniak 2010). T-cell-mediated (type IV) reactions (eg, maculopapular rash) are less understood and it is not possible to completely exclude this potential based on current insights. In cases where prior reactions were severe (Stevens-Johnson syndrome/TEN), some clinicians choose to avoid exposure to these classes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Allergies/asthma: Use with caution in patients with allergies or asthma. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Glucose 6-phosphate dehydrogenase (G6PD) deficiency: Use with caution in patients with G6PD deficiency; hemolysis may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage modification required. Maintain adequate hydration to prevent crystalluria.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neonates: Sulfa antibiotics have been shown to displace bilirubin from protein binding sites which may potentially lead to hyperbilirubinemia and kernicterus in neonates and young infants; do not use in neonates; avoid use in infants &lt;2 months unless other options are not available.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol;  large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse  (AAP [&quot;Inactive&quot; 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates.  See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Not for the treatment of group A beta-hemolytic streptococcal infections.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223797\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2C9 (major), CYP2E1 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (strong)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223754\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12814&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: Sulfonamides may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alitretinoin (Systemic): CYP2C9 Inhibitors (Strong) may increase the serum concentration of Alitretinoin (Systemic).  Management: Consider reducing the alitretinoin dose to 10 mg when used together with strong CYP2C9 inhibitors. Monitor for increased alitretinoin effects/toxicities if combined with a strong CYP2C9 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Androgens: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<b> Exceptions: </b>Danazol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Bosentan.  Management: Concomitant use of both a CYP2C9 inhibitor and a CYP3A inhibitor or a single agent that inhibits both enzymes with bosentan is likely to cause a large increase in serum concentrations of bosentan and is not recommended. See monograph for details.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol serum concentrations may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carvedilol: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP2C9 Substrates (High risk with Inhibitors). Management: Concurrent use of ceritinib with a CYP2C9 substrate that has a narrow therapeutic index (eg, warfarin, phenytoin) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloroprocaine: May diminish the therapeutic effect of Sulfonamide Antibiotics. Management: Avoid concurrent use of chloroprocaine and systemic sulfonamide-based antimicrobials whenever possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Sulfonamide Antibiotics may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Sulfonamide Antibiotics may decrease the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inducers (Moderate): May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Substrates (High risk with Inhibitors): CYP2C9 Inhibitors (Strong) may decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP2C9 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexketoprofen: May enhance the adverse/toxic effect of Sulfonamides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diclofenac (Systemic): CYP2C9 Inhibitors (Strong) may increase the serum concentration of Diclofenac (Systemic).  Management: Consider using a lower dose of diclofenac when used together with a strong CYP2C9 inhibitor.  Arthrotec (diclofenac and misoprostol) labeling specifically recommends limiting the total daily dose to a maximum of 50 mg twice/day.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Dronabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP2C9 substrates that have a narrow therapeutic index should be avoided. Use of enzalutamide and any other CYP2C9 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Lacosamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lornoxicam: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Lornoxicam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor may increase the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Sulfonamides may enhance the adverse/toxic effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methenamine: May enhance the adverse/toxic effect of Sulfonamide Antibiotics. Specifically, the combination may result in the formation of an insoluble precipitate in the urine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Sulfonamide Antibiotics may enhance the adverse/toxic effect of Methotrexate.  Management: Consider avoiding concomitant use of methotrexate and either sulfamethoxazole or trimethoprim. If used concomitantly, monitor for the development of signs and symptoms of methotrexate toxicity (eg, bone marrow suppression).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP2C9 Substrates (High risk with Inhibitors). Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when nitric oxide is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ospemifene: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Ospemifene. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parecoxib: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Parecoxib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegvisomant: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium P-Aminobenzoate: May diminish the therapeutic effect of Sulfonamide Antibiotics.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Procaine: May diminish the therapeutic effect of Sulfonamide Antibiotics.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prothionamide: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pyrimethamine: May enhance the adverse/toxic effect of Sulfonamide Antibiotics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Quinolones may diminish the therapeutic effect of Blood Glucose Lowering Agents. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramelteon: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Ramelteon. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifapentine: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonylureas: Sulfonamide Antibiotics may enhance the hypoglycemic effect of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracaine (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Sulfonamide Antibiotics may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223773\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Vitamin C or acidifying agents (cranberry juice) may cause crystalluria. Management: Avoid large quantities of vitamin C or acidifying agents (cranberry juice). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223756\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8774446\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events have been observed in animal reproduction studies. Sulfadiazine crosses the placenta (Speert, 1943). Available studies and case reports have failed to show an increased risk for congenital malformations after sulfadiazine use (Heinonen, 1977); however, studies with sulfonamides as a class have shown mixed results (ACOG, 2011).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Sulfadiazine is recommended for use in pregnant women to prevent <i>T. gondii</i> infection of the fetus, for the maternal treatment of <i>Toxoplasmic gondii</i> encephalitis, and as an alternative agent for the secondary prevention of rheumatic fever (CDC, 2009; DHHS, 2013; Gerber, 2009). Sulfonamides may be used to treat other infections in pregnant women when clinically appropriate for confirmed infections caused by susceptible organisms; use during the first trimester should be limited to situations where no alternative therapies are available (ACOG, 2011). Because safer options are available for the treatment of urinary tract infections in pregnant women, use of sulfonamide-containing products &gt;32 weeks gestation should be avoided (Lee, 2008). Due to the theoretical increased risk for hyperbilirubinemia and kernicterus, sulfadiazine is contraindicated by the manufacturer for use near term. Neonatal healthcare providers should be informed if maternal sulfonamide therapy is used near the time of delivery (DHHS, 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050007\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC, renal function tests, urinalysis; signs of serious blood disorders (sore throat, fever, pallor, purpura, jaundice); CD4+ count in HIV-exposed/-positive patients treated for toxoplasmosis; sulfonamide blood concentrations may be monitored for severe infections (target: 12-15 mg/100 mL); observe for change in bowel frequency</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223748\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Interferes with bacterial growth by inhibiting bacterial folic acid synthesis through competitive antagonism of PABA</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223763\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Well absorbed </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Throughout body tissues and fluids including pleural, peritoneal, synovial, and ocular fluids; throughout total body water; readily diffused into CSF</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 38% to 48%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Via N-acetylation </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 10 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Within 3-6 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (43% to 60% as unchanged drug, 15% to 40% as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11448585\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">A 200 mg/mL oral suspension may be made with sulfadiazine powder and sterile water. Place 50 g sulfadiazine powder in a glass mortar. Add small portions of sterile water and mix to a uniform paste; mix while incrementally adding sterile water to <b>almost</b> 250 mL; transfer to a calibrated bottle, rinse mortar with sterile water, and add sufficient quantity of sterile water to make 250 mL. Label &quot;shake well&quot; and &quot;refrigerate&quot;. Stable for 3 days refrigerated. <b>Note:</b> Suspension may also be prepared by crushing one-hundred 500 mg tablets; however, it is stable for only 2 days.</p>\n    <div class=\"reference\">Pathmanathan U, Halgrain D, Chiadmi F, et al, &quot;Stability of Sulfadiazine Oral Liquids Prepared From Tablets and Powder,&quot; <i>J Pharm Pharm Sci</i>, 2004, 7(1):84-7.<span class=\"pubmed-id\">15144740</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2524726\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (SulfADIAZINE Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $504.74</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038834\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adiazin (FI);</li>\n      <li>Adiazine (FR);</li>\n      <li>Labdiazina (PT);</li>\n      <li>Sulfadiazin Streuli (CH);</li>\n      <li>Sulfadiazin-Heyl (DE);</li>\n      <li>Sulfadiazina (IT);</li>\n      <li>Sulfadiazina Reig Jofre (ES);</li>\n      <li>Sulfadiazine (GB);</li>\n      <li>Sulfadiazine Suspensie FNA (NL);</li>\n      <li>Sulzine (LK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfadiazine-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice, &quot;ACOG Committee Opinion No. 494: Sulfonamides, Nitrofurantoin, and Risk of Birth Defects,&quot; <i>Obstet Gynecol</i>, 2011, 117(6):1484-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfadiazine-pediatric-drug-information/abstract-text/21606771/pubmed\" target=\"_blank\" id=\"21606771\">21606771</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children: Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics,&rdquo; <i>MMWR Recomm Rep</i>, 2009, 58(RR-11):1-166. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfadiazine-pediatric-drug-information/abstract-text/19730409/pubmed\" target=\"_blank\" id=\"19730409\">19730409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <i>MMWR Recomm Rep</i>. 2009a;58(RR-4):1-207. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfadiazine-pediatric-drug-information/abstract-text/19357635/pubmed\" target=\"_blank\" id=\"19357635\">19357635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.  <a>http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfadiazine-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Della-Giustina K and Chow G, &quot;Medications in Pregnancy and Lactation,&quot; <i>Emerg Med Clin North Am</i>, 2003, 21(3):585-613.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfadiazine-pediatric-drug-information/abstract-text/12962348 /pubmed\" target=\"_blank\" id=\"12962348 \">12962348 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections (OI) in HIV-Infected Adults and Adolescents, &quot;Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations From the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA),&quot;  May 7, 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frenkel JK, &ldquo;Toxoplasmosis,&rdquo; <i>Pediatr Clin North Am</i>, 1985, 32(4):917-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfadiazine-pediatric-drug-information/abstract-text/3895139/pubmed\" target=\"_blank\" id=\"3895139\">3895139</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gerber MA, Baltimore RS, Eaton CB, et al, &quot;Prevention of Rheumatic Fever and Diagnosis and Treatment of Acute <i>Streptococcal pharyngitis</i>: A Scientific Statement From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics,&quot; Circulation, 2009, 119(11):1541-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfadiazine-pediatric-drug-information/abstract-text/19246689/pubmed\" target=\"_blank\" id=\"19246689\">19246689</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heinonen OP, Slone D, and Shapiro S, <i>Birth Defects and Drugs in Pregnancy </i>, Littleton, MA: Publishing Sciences Group, Inc, 1977. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee M, Bozzo P, Einarson A, et al, &quot;Urinary Tract Infections in Pregnancy,&quot; <i>Can Fam Physician</i>, 2008, 54(6):853-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfadiazine-pediatric-drug-information/abstract-text/18556490/pubmed\" target=\"_blank\" id=\"18556490\">18556490</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lerner PI. Nocardiosis. <i>Clin Infect Dis</i>. 1996;22(6):891-903.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfadiazine-pediatric-drug-information/abstract-text/8783685/pubmed\" target=\"_blank\" id=\"8783685\">8783685</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <i>Red Book: 2012 Report of the Committee on Infectious Diseases</i>, &quot;Antibacterial Drugs Dosage Tables,&quot; 29th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2012, 808-16. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schmidt DR, Hogh B, Andersen O, et al, &quot;Treatment of Infants With Congenital Toxoplasmosis: Tolerability and Plasma Concentrations of Sulfadiazine and Pyrimethamine,&quot;<i> Eur J Pediatr</i>, 2006, 165(1):19-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sulfadiazine-pediatric-drug-information/abstract-text/16133245/pubmed\" target=\"_blank\" id=\"16133245\">16133245</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Speert H, &quot;Placental Transmission of Sulfathiazole and Sulfadiazine and its Significance for Fetal Chemotherapy,&quot; <i>Am J Obstet Gynecol</i>, 1943, 45:200-7.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12814 Version 116.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1050008\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11445119\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1050001\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F223759\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F223745\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1050011\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F3149216\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1050010\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F223809\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F223807\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F223764\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F223749\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F223797\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F223754\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F223773\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F223756\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8774446\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1050007\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F223748\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F223763\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F11448585\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F2524726\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038834\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12814|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=sulfadiazine-drug-information\" class=\"drug drug_general\">Sulfadiazine: Drug information</a></li><li><a href=\"topic.htm?path=sulfadiazine-patient-drug-information\" class=\"drug drug_patient\">Sulfadiazine: Patient drug information</a></li></ul></div></div>","javascript":null}